Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Airbnb
TI
TickerTickle
Community Contributor
Airbnb (ABNB): Still one of the most interesting bets in travel
Key insights Airbnb is changing from a travel-only app to a full lifestyle platform (stays, rentals, experiences) International markets are growing faster than the US, which is slowing down Product experience is improving a lot, with AI making search and booking easier Regulations are becoming a big risk, especially in Europe where listings are getting removed The way people move around the world has changed. It’s not only about holidays anymore.
View narrative
US$163.75
FV
23.9% undervalued
intrinsic discount
12.00%
Revenue growth p.a.
Set Fair Value
8
users have liked this narrative
0
users have commented on this narrative
34
users have followed this narrative
New
narrative
ING Groep
PI
PittTheYounger
Community Contributor
ING leads the pack when it comes to pivoting towards non-lending income
ING, of course, is a bank; and banks don't like falling interest rates, right? For the dominant stream of income is their core business model, i.e. borrowing short-term and lending long-term, reaping the difference in interest rates in the process.
View narrative
€27.92
FV
23.7% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
4
users have liked this narrative
0
users have commented on this narrative
12
users have followed this narrative
New
narrative
Coles Group
RO
Robbo
Community Contributor
Coles (ASX: COL): Safe, Steady, and Surprisingly Cheap
The supermarket chain Coles is the kind of “boring” business that may have been overlooked as an investment opportunity. Although it was divested from Wesfarmers in 2018, Coles’ heritage traces back to 1914 — giving it over 110 years of history.
View narrative
AU$22.00
FV
4.0% undervalued
intrinsic discount
8.72%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
2
users have commented on this narrative
15
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Innate Pharma
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
Clinical Trial Enrollment And FDA Designation Will Open Oncology Opportunities
Key Takeaways A robust pipeline of innovative oncology therapeutics and drug candidates highlights strong R&D productivity potentially leading to substantial future earnings. Strategic partnerships, breakthrough therapy designations, and clinical trial progression indicate potential accelerated market entry and revenue growth in oncology treatments.
View narrative
€4.35
FV
55.5% undervalued
intrinsic discount
44.23%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
5
users have followed this narrative
7 days ago
author updated this narrative
Quantum
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
Subscription Model And DXi Sales Will Drive Future Success
Key Takeaways Quantum's shift to a subscription model boosts recurring revenue, enhancing profitability and cash flow stability amid growing ARR. Strategic equity and cost improvements reduce debt and enhance margins, while product and international deal growth bolster future earnings.
View narrative
US$19.00
FV
57.9% undervalued
intrinsic discount
1.59%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
11
users have followed this narrative
7 days ago
author updated this narrative
Coherus Oncology
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Global Cancer Trends Will Benefit Immune-Oncology Pipeline Despite Setbacks
Key Takeaways Strategic shift to immuno-oncology and partnerships is driving clinical progress, operational efficiency, and positions the company for growth in innovative cancer therapies. Divestiture of biosimilar assets and cost reductions should improve margins and allow greater investment in high-potential oncology pipeline programs.
View narrative
US$4.70
FV
78.7% undervalued
intrinsic discount
-23.36%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
10
users have followed this narrative
7 days ago
author updated this narrative
Hexagon Purus
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
European Incentives And Cost Cuts Will Advance Hydrogen Mobility
Key Takeaways Government incentives and expanding partnerships are boosting demand and positioning Hexagon Purus for recurring revenue and margin improvements in zero-emission mobility markets. Cost reduction initiatives and a diversified order backlog enhance profitability, reduce risk, and provide strong forward revenue visibility amidst decarbonization trends.
View narrative
NOK 3.37
FV
48.0% undervalued
intrinsic discount
38.39%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
4
users have followed this narrative
7 days ago
author updated this narrative
Nektar Therapeutics
AN
AnalystConsensusTarget
Consensus Narrative from 6 Analysts
Phase IIb Data And FDA Fast-Track Will Spur Mixed Prospects
Key Takeaways Fast-track designation and strategic partnerships could expedite REZPEG's market entry, enhancing near-term revenue and profit margins. Strong financial reserves enable sustained R&D investment, supporting pipeline expansion and potential revenue diversification.
View narrative
US$94.83
FV
72.9% undervalued
intrinsic discount
-24.38%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
9
users have followed this narrative
7 days ago
author updated this narrative
Sutro Biopharma
AN
AnalystConsensusTarget
Consensus Narrative from 7 Analysts
ADC Pipeline Focus Will Advance Preclinical Drug Development
Key Takeaways Strategic focus on preclinical programs and restructuring is set to drive future growth by enhancing drug development and revenue potential. Workforce reduction and externalization aim to improve margins and extend the cash runway, while partnerships and out-licensing bolster financial flexibility.
View narrative
US$3.26
FV
76.3% undervalued
intrinsic discount
-12.32%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
7 days ago
author updated this narrative
Biodesix
AN
AnalystConsensusTarget
Consensus Narrative from 4 Analysts
Sales Force Expansion And CLARIFY Study Will Boost Test Adoption
Key Takeaways Expansion of sales force and test adoption, along with CLARIFY study results, are expected to drive revenue growth and improve margins. Diagnostic services growth and potential profitability could enhance investor confidence and diversify revenues through new partnerships and innovative test developments.
View narrative
US$1.80
FV
78.7% undervalued
intrinsic discount
18.78%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
7 days ago
author updated this narrative
Alector
AN
AnalystConsensusTarget
Consensus Narrative from 7 Analysts
ABC Platform And Latozinemab Trial Will Yield Mixed Prospects
Key Takeaways Alector's ABC platform and late-stage trials, like those for latozinemab, could significantly boost revenue if successful, addressing unmet medical needs. Strong cash reserves support pipeline progression, potentially stabilizing R&D costs and enhancing net margins as programs near commercialization.
View narrative
US$4.93
FV
55.8% undervalued
intrinsic discount
38.45%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
7 days ago
author updated this narrative
Inseego
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Restructuring The Balance Sheet And Expanding FWA Will Secure Stability
Key Takeaways Strategic focus on scaling fixed wireless access and MiFi businesses aligns with global wireless broadband demand, potentially driving revenue growth. Increased emphasis on software and services through Inseego Connect can enhance gross margins with recurring revenue and stabilize earnings.
View narrative
US$11.50
FV
19.8% undervalued
intrinsic discount
2.10%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
7 days ago
author updated this narrative
Value any company in seconds
Popular companies